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Abstract
Background: Pancreatic cancer has an extremely poor prognosis and prolonged survival is achieved only by resection with
macroscopic tumor clearance. There is a strong rationale for a neoadjuvant approach, since a relevant percentage of
pancreatic cancer patients present with non-metastatic but locally advanced disease and microscopic incomplete resections
are common. The objective of the present analysis was to systematically review studies concerning the effects of
neoadjuvant therapy on tumor response, toxicity, resection, and survival percentages in pancreatic cancer.
Methods and Findings: Trials were identified by searching MEDLINE, EMBASE, and the Cochrane Central Register of
Controlled Trials from 1966 to December 2009 as well as through reference lists of articles and proceedings of major
meetings. Retrospective and prospective studies analyzing neoadjuvant radiochemotherapy, radiotherapy, or chemother-
apy of pancreatic cancer patients, followed by re-staging, and surgical exploration/resection were included. Two reviewers
independently extracted data and assessed study quality. Pooled relative risks and 95% confidence intervals were calculated
using random-effects models. Primary outcome measures were proportions of tumor response categories and percentages
of exploration and resection. A total of 111 studies (n=4,394) including 56 phase I–II trials were analyzed. A median of 31
(interquartile range [IQR] 19–46) patients per study were included. Studies were subdivided into surveys considering initially
resectable tumors (group 1) and initially non-resectable (borderline resectable/unresectable) tumors (group 2). Neoadjuvant
chemotherapy was given in 96.4% of the studies with the main agents gemcitabine, 5-FU (and oral analogues), mitomycin
C, and platinum compounds. Neoadjuvant radiotherapy was applied in 93.7% of the studies with doses ranging from 24 to
63 Gy. Averaged complete/partial response probabilities were 3.6% (95% CI 2%–5.5%)/30.6% (95% CI 20.7%–41.4%) and
4.8% (95% CI 3.5%–6.4%)/30.2% (95% CI 24.5%–36.3%) for groups 1 and 2, respectively; whereas progressive disease
fraction was estimated to 20.9% (95% CI 16.9%–25.3%) and 20.8% (95% CI 14.5%–27.8%). In group 1, resectability was
estimated to 73.6% (95% CI 65.9%–80.6%) compared to 33.2% (95% CI 25.8%–41.1%) in group 2. Higher resection-
associated morbidity and mortality rates were observed in group 2 versus group 1 (26.7%, 95% CI 20.7%–33.3% versus
39.1%, 95% CI 29.5%–49.1%; and 3.9%, 95% CI 2.2%–6% versus 7.1%, 95% CI 5.1%–9.5%). Combination chemotherapies
resulted in higher estimated response and resection probabilities for patients with initially non-resectable tumors (‘‘non-
resectable tumor patients’’) compared to monotherapy. Estimated median survival following resection was 23.3 (range 12–
54) mo for group 1 and 20.5 (range 9–62) mo for group 2 patients.
Conclusions: In patients with initially resectable tumors (‘‘resectable tumor patients’’), resection frequencies and survival
after neoadjuvant therapy are similar to those of patients with primarily resected tumors and adjuvant therapy.
Approximately one-third of initially staged non-resectable tumor patients would be expected to have resectable tumors
following neoadjuvant therapy, with comparable survival as initially resectable tumor patients. Thus, patients with locally
non-resectable tumors should be included in neoadjuvant protocols and subsequently re-evaluated for resection.
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading
cause of cancer-related mortality [1] and is associated with an
extremely poor prognosis, reflected by a median survival of 5–
8 mo and a 5-y survival probability of less than 5% when all stages
are combined [1–3]. At present, the only chance for cure and
prolonged survival is surgical resection with macroscopic tumor
clearance. However, only approximately 10%–20% [1,4] of
patients are considered candidates for curative resection. The
majority of patients (50%–60%) present with metastatic disease,
and thus palliative chemotherapy remains the only option for
almost all of these patients [5].
In a substantial number of patients (approximately 30%–40%)
the disease is considered ‘‘locally advanced’’ at the time of diagnosis.
This group of patients has been intensively discussed during the last
years and neoadjuvant therapies have been proposed to achieve
better local tumor control or tumor down-staging with a subsequent
potentially resectable tumor [6]. Neoadjuvant therapy in this
context is defined as any preoperative therapy aiming to convert
unresectable to resectable tumors and/or to increase microscopic
complete tumor resection rates. Unfortunately, however, no data
regarding the role of neoadjuvant therapy for pancreatic cancer
from randomized phase III trials are available. In addition, a
thorough analysis of this group of patients has been hampered by
the lack of an accepted and widely used definition of resectability
and unresectability. For example, while current guidelines generally
consider encasement/involvement of the superior mesenteric
artery/celiac trunk as signs of unresectability [7,8], portal vein/
superior mesenteric vein involvement has been more critically
discussed [9] and categories such as ‘‘borderline resectable’’ have
beenintroduced [8].Furthermore, all criteriadepend heavilyon the
experience and technical expertise of the involved radiologists,
gastroenterologists, and surgeons.
Even following potential curative resection more than 80% of
the patients ultimately die of the disease due to local recurrence
and/or distant metastasis. The high rate of local recurrence [10] is
predetermined by the microscopic frequently incomplete resec-
tions [11–13] as a result of the anatomical location of the tumor
and the growth pattern of pancreatic cancer cells. Adjuvant
therapy [14–16] has been established as the standard of care
following resection for pancreatic adenocarcinoma. Here, solid
data from randomized controlled trials [17–22] suggest that
adjuvant chemotherapy (gemcitabine or 5-FU) is the standard
treatment option. In contrast, there is still discussion regarding the
role of adjuvant chemoradiation [20,23] specifically in the
subgroup of patients with positive resection margins [15].
The relatively high percentage of PDAC patients presenting
with non-metastatic but ‘‘locally advanced’’ disease as well as the
large number of microscopic incomplete resections [11,13] should
provide a strong rationale for a neoadjuvant approach. Although
neoadjuvant therapy for pancreatic cancer has been proposed for
more than two decades [24,25], and although there is strong
evidence of its benefit for other tumor entities, up to now there is
no compelling evidence for a clinical benefit of neoadjuvant
therapy in pancreatic cancer. Here, we systematically reviewed
and performed a meta-analysis of the available data regarding
neoadjuvant chemo- and/or radiotherapy with special emphasis
on tumor response/progression rates, toxicities, and clinical
benefit, i.e. resection probabilities and survival estimates.
Methods
Although no randomized phase III trials could be considered
within this review, general recommendations from QUOROM
[26] and the PRISMA revision [27] with regard to processing and
reporting of results were taken into account (Text S1).
Trial Criteria
This systematic review and meta-analysis incorporated retro-
spective and prospective studies of patients with pancreatic and
periampullary cancer with the following design: neoadjuvant
radiochemotherapy, radiotherapy, or chemotherapy, followed by
re-staging, and surgical exploration/resection in selected patients.
Phase I–II clinical trials, cohort studies, and case series were
included. Case reports were excluded as were reports of identical
patient cohorts (if clearly identifiable).
Search Strategy
Trials were identified by searching MEDLINE, EMBASE, and
the Cochrane Central Register of Controlled Trials from 1966 to
December 2009 (Text S2). The search strategy included the
following search keys: (‘‘pancreas’’ or ‘‘pancreatic’’) and (‘‘cancer’’
or ‘‘carcinoma’’) and (‘‘neoadjuvant’’ or ‘‘preoperative’’) and
(‘‘radiation’’ or ‘‘chemoradiation’’ or ‘‘chemotherapy’’), without
language restriction. The results were then hand-searched for
eligible studies. Furthermore we searched the proceedings of the
Gastrointestinal Cancers Symposium and ASCO Annual Meeting
from 2004 to December 2009. In addition, reference lists of the
selected trials were screened for any other relevant study.
Prospective and ongoing trials were identified by searching the
following prospective trials registers and databases (last search
December 1, 2009): ISRCTN Register, Action Medical Research,
Leukaemia Research Fund, Medical Research Council (UK),
National Health Service Research and Development Health
Technology Assessment Programme (HTA), National Institutes
of Health (www.ClinicalTrials.gov), The Wellcome Trust and the
UK Clinical Trials Gateway, and The WHO International
Clinical Trials Registry Platform (www.who.int/ictrp) including
the Australian New Zealand Clinical Trials Registry (ANZCTR),
Chinese Clinical Trial Register (ChiCTR), Clinical Trials
Registry–India (CTRI), German Clinical Trials Register (DRKS),
Iranian Registry of Clinical Trials (IRCT), Sri Lanka Clinical
Trials Registry (SLCTR), and The Netherlands National Trial
Register (NTR). The search strategy for these trials included the
following search keys: ((‘‘pancreas’’ or ‘‘pancreatic’’) and (‘‘cancer’’
or ‘‘carcinoma’’) and (‘‘neoadjuvant’’ or ‘‘preoperative’’)) or
((‘‘pancreas’’ or ‘‘pancreatic’’) and (‘‘cancer’’ or ‘‘carcinoma’’)
and (‘‘non-metastatic’’ or ‘‘nonmetastatic’’) and (‘‘unresectable’’ or
‘‘non-resectable’’ or ‘‘locally advanced’’)), without language
restriction.
Selection of Trials and Data Collection
Two reviewers (SG, JK) independently assessed the eligibility of
abstracts identified by the search. The full-text article of any trial
that appeared to meet the inclusion criteria was retrieved for closer
examination. Disagreements were resolved by consensus. The
same reviewers extracted the data independently using standard-
ized data collection forms. Data retrieved from the reports include
publication details (year of publication, study center), methodo-
logical components, and trial characteristics, such as sample size,
interventions (radiochemotherapy, radiotherapy, or chemothera-
py), and outcome measures (Text S2). Included studies were
subdivided into three groups: those studies analyzing patients with
pancreatic and periampullary cancer who were judged resectable
on preoperative staging (group 1), those studies analyzing patients
whose tumors were judged borderline resectable or unresectable
(subsequently termed non-resectable; group 2), and those studies
that included all patients with localized non-metastatic disease
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to the utilized resectability criteria and grouped according to the
current National Comprehensive Cancer Network (NCCN)
criteria for resectability [28] if applicable. In cases where
resectability criteria were not or not clearly stated, tumors were
grouped according to the stated resectability category.
Outcome Measures
The primary outcome measures were proportions of tumor
response categories (CR, PR, SD, PD) as well as percentages of
exploration and resection. Secondary outcome measures included
toxicity, morbidity, mortality, and survival. The authors aimed to
unify definitions of tumor response across studies in accordance
with the RECIST criteria [29]: Complete response: disappearance
of all target lesions (radiographic) or no vital tumor cells
(histopathological); partial response: 30% decrease of the target
lesion (radiographic) or marked signs of tumor regression
(histopathologic); progressive disease: 20% increase of the target
lesion (radiographic), or distant metastases (radiographic or
histopathologic); stable disease: no change or small changes that
did not meet the above criteria. In case of discrepant radiological
and histopathological response, the histopathological response was
taken for calculation.
Quality Assessment
To assess the overall strength/quality of evidence for the various
outcome parameters, a quality assessment was carried out in the style
of the GRADEprofiler (GRADEpro. [Computer program]. Version
3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schu ¨nemann,
2008). Study design, study limitation, risk of bias, study inconsistency,
indirectness, and imprecision were rated according to the GRADE-
profiler. Study quality was classified as high, moderate, low, or very
low. Outcome parameters were classified as critical, important but
not critical, or of limited importance.
Statistical Analysis
The statistical software package R version 2.7.1 (R Foundation
for Statistical Computing, Vienna, Austria) with function metaprop
(R package: meta, Schwarzer 2008) was used for the statistical
analyses. Pooled estimates of proportions with corresponding 95%
confidence intervals were calculated on the base of the Freeman-
Tukey double arcsine transformation [30,31] within a random
effect model framework. Heterogeneity of combined study results
was assessed by inconsistency statistic (I
2) and its connected chi-
square test for heterogeneity, and I
2 and the corresponding 95%
confidence intervals were calculated. No formal test was
conducted for purpose of subgroup comparisons and results were
solely displayed in a comparative descriptive manner. References
from literature [32] as well as especially conducted preliminary
simulation studies suggest that unbiased pooled estimates of
median survival times cannot be achieved by simple weighted
averaging of medians. A more appropriate approach is achieved
by averaging parameter estimates of a presumed density function
of survival and recalculating the estimate of median from the
pooled distribution parameter. A reasonable distribution of
survival times which implies a time constant hazard rate
corresponding to the sole distribution parameter l is given by
the exponential distribution. Following this assumption, a weighted
estimate of population median (mp) survival is derived by:
mp~
X k
i~1
wi
mi
 ! {1
where mi denotes the median survival within a study population i
(with i from 1 to k) and wi refers a study specific weight function,
and Swi=1. Since no sufficient information on patients at risk for
median survival times was available from the considered studies,
number of study participants (divided by the total number of
evaluable patients) was used as weights. Confidence intervals for
median estimates were not calculable and therefore the range of
medians was provided instead of confidence limits. In order to
analyze potential publication bias, funnel plots were created for
the outcome parameters using a Web-based software tool (Eastern
Region Public Health Observatory (erpho); tools.erpho.org.uk/bino-
mial.aspx). Graphs were plotted using GraphPad Prism 5 for
Windows (GraphPad, San Diego, CA).
Analysis of Heterogeneity
The general linear modeling framework to extract sources of
variance (heterogeneity) from the study data was used. For this
purpose, variables potentially explaining clinical incomparability
and design incomparability, respectively, were considered in the
meta-regression analysis following the terminology of Thompson
[33]. These variables were resectability (yes, no, both, or not
defined), resectability criteria (NCCN criteria [28], clearly
defined criteria, not clearly defined, or no stated criteria), mean
age of patients (5-y intervals), mean year of study interval
Figure 1. Number of identified original studies (n=111) and reviews (n=85) per year (1980–2009).
doi:10.1371/journal.pmed.1000267.g001
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py), institution and study design (phase I, phase I/II, phase II,
cohort study, case series, retrospective, prospective), and
evaluation criteria (RECIST criteria [29], clearly defined
criteria, not clearly defined, or no stated criteria). For purpose
of a reliable statistical analysis, arcsine transformation was
applied first to the main outcome parameters (proportions, e.g.
fraction of resected and explored patients, respectively). The
number of patients for each specific outcome parameter was
considered as residual weight within the regression model and
Table 1. Summary of included studies in the different defined groups.
Group Total Number of Studies (%) Patients per Study Median (IQR)
All patients 111 31 (19–46)
Group 1 (tumor resectable before treatment) 35 (31.5%) 32 (20–50)
Group 2 (tumor non-resectable before treatment) 57 (51.4%) 27 (18–38)
Group 3 (both or not defined) 19 (17.1%) 38 (24–82)
doi:10.1371/journal.pmed.1000267.t001
Figure 2. Depiction of utilized chemotherapy and radiotherapy. (A) Schematic overview of the used chemotherapeutic agents. diff. regimen,
studies comparing/using different drug regimen (n=28); no CTx, no chemotherapy applied (only radiotherapy). (B) Schematic overview of the
applied radiation doses. Studies are summarized within a range of applied doses. Data included are per protocol, not all patients received the stated
dose. diff. regimen, different radiation doses applied; not specified, radiation applied, dose not specified; no RTx, no radiotherapy applied (only
chemotherapy).
doi:10.1371/journal.pmed.1000267.g002
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component. The main outcome parameters were (transformed)
proportions; therefore percentages of explained variability have
to be interpreted in a relative (comparative) manner rather than
in an absolute one.
Results
From 515 initially retrieved studies, 111 studies published since
1980 were identified and included in this systematic review and
meta-analysis (Figure S1, Table S1). Four studies overlapped with
four of the 111 studies, and were therefore excluded. In the same
time period, 85 reviews regarding neoadjuvant therapy in
pancreatic cancer were published. The number of published
original and review articles increased steadily within the last 15
years (Figure 1).
The 111 reviewed trials included 4,394 patients. Seventeen
centers published more than 1 study, altogether accounting for 73
of the 111 studies (Table S1). Eight of the 17 centers published 2
studies. The University of Texas M.D. Anderson Cancer Center
(Houston, TX) and the Fox Chase Cancer Center (Philadelphia,
PA) published 12 and 11 studies, respectively (Table S1). Other
centers such as University of Osaka (Japan), the University of
Marseille (France), and the Duke University (Durham, NC)
published 8, 6, and 5 studies, respectively. The potentially
overlapping patient populations were difficult to calculate since
the information of which patients were included in which analysis
could not always be retrieved. Using the study periods, study
protocols, and a conservative estimate, there was a maximum of
17% overlapping patient populations.
Of the 111 included studies, 78 studies were prospective and 33
retrospective. There were 15 phase I, 13 phase I/II, and 28 phase
II studies, as well as 14 cohort studies and 41 case series. No phase
III trials have been published so far. A systematic search of clinical
trial databases for pancreatic cancer trials identified 17 neoadju-
vant trials (all phase I–II trials) and 23 trials for non-resectable but
non-metastatic pancreatic cancer, i.e. potentially neoadjuvant
trials (Table S2).
The 111 analyzed studies reported on PDAC that generally
included pancreatic head, corpus, and tail tumors without separate
analysis regarding tumor localization. The studies included a
median (IQR) of 31 (19–46) patients (Table 1). Ten of the 111
studies included in addition to pancreatic cancer a few patients
with other periampullary tumors (i.e. ampullary, distal bile duct,
and duodenal cancer), without separate analysis of the different
entities. In 84 studies (76%), it was explicitly stated that histological
or cytological tumor diagnosis was obtained before therapy. The
age of the included patients varied, as did its reporting. The
median of reported age of the patients in the 94 assessable studies
was 62.5 y and was similar in the analyzed groups (group 1: 62 y,
group 2: 62 y).
Chemotherapy
Chemotherapy was applied as neoadjuvant treatment in 107 of
the 111 studies (96.4%). Different combinations of chemothera-
pies/agents and dosages were tested, as 56 of the studies were
phase I–II trials. The main agents were gemcitabine, 5-FU (and
oral analogues), mitomycin C, and platinum compounds
(Figure 2A). In the trials that used only one regimen (n=79), 43
(54.4%) were performed using 5-FU or its oral analogues. 5-FU
monotherapy was given in 14 (17.7%) of the studies. Thirty-six
(45.6%) of the studies used a gemcitabine-based regimen, and of
those, 18 (22.8%) studies applied gemcitabine monotherapy. 5-FU
and gemcitabine combinations were used in 3 studies. Several
studies compared different schemes or agents. Five studies were
performed comparing gemcitabine with 5-FU or capecitabine, two
studies comparing gemcitabine with cisplatin, two gemcitabine
with 5-FU/cisplatin, and another three gemcitabine with 5-FU/
mitomycin C. A further 16 studies included different agents and
combinations (some for only few patients) (Table S1). Twelve trials
included taxanes (docetaxel/paclitaxel) in different combinations
or as monotherapy (n=3). Five of the 107 studies included
antibodies or tyrosine kinase inhibitors (bevacizumab, cetuximab,
erlotinib) in the chemotherapeutic regimen. There were 44 studies
using single agents (alone or in comparison) and 48 studies using
combination therapies. In 15 studies both single agents and
combination therapies were utilized.
Radiotherapy
In 104 of the 111 studies (93.7%) patients received neoadjuvant
radiotherapy. In three studies the exact radiation dose was not
given. Doses applied ranged from 24 Gy to 63 Gy (Figure 2B). In
52 of the 104 studies that included radiotherapy the patients
received doses between 45 and 50.4 Gy. In 14 studies different
doses and radiation schedules were compared. Most patients
received 1.8 Gy/fraction (50/104 studies), 2 Gy/fraction (15/
104), or 3 Gy/fraction (10/104). In 13 studies intraoperative
radiation (IORT) was applied with doses between 10 and 30 Gy.
Since in most of those studies only few patients received IORT,
this aspect was not further analyzed.
Toxicity
Data regarding treatment-related toxicity were available for 63 of
111 studies. For subsequent analysis, only severe(grade 3/4) toxicity
(National Cancer Institute Common Toxicity Criteria; ctep.can-
cer.gov) was taken into account. Grade 3/4 toxicity for neoadjuvant
therapy was estimated at 29.4% (CI 23.1%–36.1%) for all patients
and was comparable for initially resectable (26.3%, CI 15.8%–
38.3%) and patients with non- resectable tumors (‘‘non-resectable
tumor patients’’) (31.1%, CI 22%–40.9%) (Table 2). Recent
randomized controlled trials for adjuvant therapy report grade 3/
4 toxicity rates for chemotherapy of 8.4%–22% (only neutropenia
[21]) and 14.7% (all toxicity [20]). The reported grade 3/4 toxicity
rates for radiochemotherapy were 9%–58% (only hematological
toxicity [34]) and 22.2%–79% (all toxicity [20]).
Tumor Response
Tumor response frequency for neoadjuvant chemo- and/or
radiation therapy was evaluated in the different studies according
Table 2. Estimates of grade 3/4 toxicity of neoadjuvant
treatment including the 95% confidence interval from the
random effect model and number of assessable studies for
each group (n).
Group Grade 3/4 Toxicity
All patients 29.4% [23.1%–36.1%]
I
2=91.3% [89.6%–92.7%]
(n=63)
Tumor resectable before treatment (group 1) 26.3% [15.8%–38.3%]
I
2=92.8% [90.3%–94.6%]
(n=22)
Tumor non-resectable before treatment (group 2) 31.1% [22.0%–40.9%]
I
2=91.6% [89.3%–93.5%]
(n=33)
doi:10.1371/journal.pmed.1000267.t002
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exploration or histopathological response after resection. Six
studies (5.4%) explicitly stated that the RECIST criteria [29]
were utilized. In 44 studies (39.6%) the criteria to assess tumor
response were clearly stated, whereas in 61 studies (55%) criteria
were either not clearly defined or not stated. For the whole study
population the estimated fraction of patients with complete
response was 3.9% (CI 3%–4.9%) (Figure 3) and with partial
response 29.1% (CI 24.5%–34%) (Figure 4). Stable disease was
averaged to 43.9% (CI 37.9%–50%) in all patients and tumor
progression under therapy occurred by estimation in 20.8% (CI
17.3%–24.6%) of the patients. Interestingly the pooled percent-
ages did not vary much in the two groups of initially deemed
resectable and non-resectable tumor patients (Table 3). Thus,
complete/partial responses were 3.6%/30.6% and 4.8%/30.2%
for groups 1 and 2, respectively; whereas progressive disease was
estimated to 20.9% (CI 16.9%–25.3%) and 20.8% (CI 14.5%–
27.8%) of primarily staged resectable and non-resectable tumor
patients. Comparing tumor response frequencies for patients
treated with mono chemotherapy (n=44) versus combination
chemotherapy (n=48) revealed complete and partial responses of
2.2% (CI 1.3%–3.3%) and 25.8% (CI 20.2%–31.8%) versus 5.3%
(CI 3.8%–7%) and 34.7% (CI 28.9%–40.9%) (Table 4).
Exploration and Resection
Operations performed included explorative laparotomies,
palliative bypass procedures, and curative resections, e.g. partial
pancreatico-duodenectomies, distal pancreatectomies, and total
pancreatectomies. Studies were analyzed for patients explored and
resected after restaging. All 111 studies included data for resection.
Seven studies (6.3%) explicitly used the NCCN guidelines of
resectability for non-metastatic pancreatic cancer [28]. Forty-five
studies (40.5%) clearly defined the resectability criteria assessing
most often the vascular involvement or classified the resectability
according to the maximal tumor dimension. In 59 studies (53.2%),
resectability criteria were not clearly stated (e.g. judged by single
surgeons or an interdisciplinary team) or not stated at all. In group
1 including the patients who were staged to be resectable before
neoadjuvant treatment resectability estimated to 73.6% (CI
65.9%–80.6%) (Figure 5, Table 3), whereas in group 2 including
the patients who were staged non-resectable before treatment the
averaged probability for resectability was 33.2% (CI 25.8%–
41.1%) (Figure 5, Table 3). As shown in Table 3, in the assessable
studies the percentage of exploration for the entire group was
69.5% (CI 62.1%–76.4%) and 77.9% (CI 72.4%–82.9%) of these
patients were resected. Of the patients deemed resectable before
treatment, 88.1% (CI 82.9%–92.4%) were explored after
restaging, and of those 85.7% (CI 78.9%–91.2%) could be
resected. In group 2, 46.9% (CI 36.9%–57.1%) of the patients
were explored. Of them, 69.9% (CI 61.2%–77.9%) could be
resected successfully (Table 3). Interestingly the estimated fraction
of R0 resections were comparable between patients in group 1
(82.1%; CI 73.1%–89.6%) and patients in group 2 (79.2%;
72.4%–85.2%) (Table 3). To analyze potential publication bias,
funnel plots were created (Figure 6) that demonstrated heteroge-
neity (see below) but no considerable imbalance (no reasonable
evidence for publication bias) neither for the group of patients with
initially resectable tumors (‘‘resectable tumor patients’’) nor for the
Figure 3. Estimates of complete response percentages in
patients following neoadjuvant therapy and re-staging includ-
ing the 95% confidence interval from the random effect model
and number of patients for each study (n).
doi:10.1371/journal.pmed.1000267.g003
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outliers in the non-resectable group (Figure 6B). Omission of these
trials in another supportive meta-analysis regarding resection rates
demonstrated an estimated resection probability of 30% (CI 24%–
36%), which was similar to the estimated proportion of 33% (CI
26%–41%) for the entire group of non-resectable tumor patients.
Analyzing resection frequencies for patients treated with mono
chemotherapy versus combination chemotherapy revealed that in
the group of initially resectable tumor patients, the averaged
fraction of resections for patients receiving monotherapy was
80.8% (CI 66.1%–92.1%) and for combination chemotherapy
66.2% (CI 57.9%–74%). In contrast, in patients with locally
advanced/unresectable tumors, resections were more frequent in
the group of patients who received combination chemotherapy
with 33% (CI 25.2%–41.3%) in comparison to monotherapy with
27.3% (CI 18.1%–37.5%) (Table 4).
Morbidity and Mortality
Data regarding morbidity and mortality following neoadjuvant
treatment and pancreatic resection were presented in 50 and 85 of
111 studies, respectively. Perioperative morbidity was estimated at
34.2% (CI 28.3%–40.4%) for all patients (Table 5), which is within
the range of reported morbidity data of 30%–55% for major
pancreatic (head) resections [35]. In-hospital mortality after
neoadjuvant treatment and tumor resection was estimated at
5.3% (CI 4.1%–6.8%) for all patients (Table 5), which is at the
upper limit of the 2%–5% mortality rates that have been reported
in large series and surveys for major pancreatic resections at high
volume centers [35–37]. Interestingly, morbidity and mortality
rates were estimated higher in the group of initially non-resectable
versus resectable tumor patients (morbidity: 39.1% versus 26.7%,
mortality: 7.1% versus 3.9%) (Table 5).
Survival Analysis
Estimates of population median survival times were calculated
as described and are provided with ranges from evaluable studies.
Survival times for the individual studies were calculated from the
time of diagnosis/start of neoadjuvant therapy in 47 trials and
from surgery/resection in 4 trials. In 60 studies no detailed
information regarding survival or survival calculations were
provided. The longest median survival (23.3 mo, range 12–54
months) was estimated for the group of initially staged resectable
tumor patients who were resected after neoadjuvant treatment
(Table 6, Figure 7). The initially non-resectable staged patients
reached an estimated median survival of 20.5 (range 9–62) mo
following resection. The estimated median survival for the entire
group of resected patients was 22.4 (range 9–62) mo. As expected,
the median survival of the entire group of patients who did not
undergo resection was shorter with 9.5 (range 6–21) mo. The
patients who were initially classified as resectable and did not
undergo resection after pretreatment survived an estimated
median of 8.4 (range 6–14) mo, compared to 10.2 (range 6–21)
mo of patients initially diagnosed as unresectable who did not
undergo resection. Estimated 1- and 2-y survival probabilities for
resected patients in group 1 were 77.9% and 47.4% and for group
2 79.8% and 50.1% (Table 6).
Analysis of Heterogeneity and Quality Assessment
The results of meta-regression, particularly the amount of
explained heterogeneity (variance components), are summarized
in Table 7. For the purpose of sensitivity analysis, particularly to
investigate sensibility of results with regard to model consider-
ations (prospective under- and/or over-fitting), both univariable
and multivariable models (simultaneously including all potential
Figure 4. Estimates of partial response percentages in patients
following neoadjuvant therapy and re-staging including the
95% confidence interval from the random effect model and
number of patients for each study (n).
doi:10.1371/journal.pmed.1000267.g004
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be identified which contributed more than one study to the total
number of trials. There were two institutions with more than 10
trials considered in our systematic review and meta-analysis. The
results of the multivariable meta-regression analysis revealed that
the amount of heterogeneity could be explained from about 13%
to 35% by differences between institutions (considered as random
effect variable). The highest impact of centers was observed
regarding toxicity (34.8%) despite simultaneous consideration of
chemotherapy, which corresponds to the next highest component
of total variability at least in the multivariable analysis. Study
design showed some impact on response evaluation (explained
variability: up to 11%) and morbidity (up to 9%). Mean age of
patients and study period are considerable explanatory variables
for heterogeneity in morbidity and in-hospital mortality with an
estimated amount of explained heterogeneity of about 10%.
Heterogeneity of resection and exploration rates could mainly be
deduced to resectability as well to differences between institutions
and there was no sufficient explanation supported by the other
potentially influencing variables. In general, the results of
univariable and multivariable heterogeneity analysis were quite
comparable. However, some range in attributable source of
outcome variability was apparent for resectability (concerning
resection and exploration rates), institution (concerning response
rates), and chemotherapy (concerning complete response rates and
toxicity) (Table 7). Quality assessment according to the GRADE-
profiler regarding toxicity analysis, response evaluation, resection
and exploration rates, morbidity, mortality, and survival analysis is
presented in Table 8.
Discussion
This comprehensive review of neoadjuvant therapy in pancre-
atic cancer aimed to evaluate the key issues, including aspects of
response and survival, and to highlight current problems and
drawbacks. Neoadjuvant protocols have been analyzed with
increasing frequency (Figure 1), as they offer a number of
hypothetical advantages over adjuvant (postoperative) therapy,
such as shorter therapy and higher therapy completion rates,
tumor down-staging with higher (R0) resection rates, and
Table 3. Estimates of exploration and resection percentages after neoadjuvant treatment and restaging, and estimates of patients
with complete response/partial response, stable disease, and progressive disease including the 95% confidence interval from the
random effect model and number of assessable studies for each group (n).
Group
Complete
Response
Partial
Response
Stable
Disease
Progressive
Disease
Explored/
All
Resected/
All
R0/
Resected
Resected/
Explored
All patients 3.9%
[3.0%–4.9%]
I
2=44.7%
[28.1%–57.5%]
(n=82)
29.1%
[24.5%–34.0%]
I
2=86.9%
[84.2%–89.1%]
(n=75)
43.9%
[37.9%–50.0%]
I
2=87.7%
[85%–89.9%]
(n=63)
20.8%
[17.3%–24.6%]
I
2=81.4%
[77.3%–84.8%]
(n=78)
69.5%
[62.1%–76.4%]
I
2=95.5%
[94.9%–96%]
(n=88)
50.7%
[44.0%–57.4%]
I
2=95.2%
[94.6%–95.7%]
(n=111)
79.6%
[74.8%–83.9%]
I
2=81.3%
[77.4%–84.6%]
(n=86)
77.9%
[72.4%–82.9%]
I
2=89%
[87%–90.6%]
(n=88)
Tumor resectable
before treatment (group 1)
3.6%
[2.0%–5.5%]
I
2=53.9%
[29.3%–70%]
(n=28)
30.6%
[20.7%–41.4%]
I
2=90.3%
[86.7%–92.9%]
(n=23)
42.1%
[30.5%–54.1%]
I
2=91.4%
[88.4%–93.6%]
(n=23)
20.9%
[16.9%–25.3%]
I
2=66.9%
[51.2%–77.5%]
(n=29)
88.1%
[82.9%–92.4%]
I
2=86.2%
[81.5%–89.7%]
(n=32)
73.6%
[65.9%–80.6%]
I
2=90.1%
[87.3%–92.3%]
(n=35)
82.1%
[73.1%–89.6%]
I
2=89.3%
[85.5%–92%]
(n=26)
85.7%
[78.9%–91.2%]
I
2=88.6%
[85%–91.4%]
(n=32)
Tumor non-resectable before
treatment (group 2)
4.8%
[3.5%–6.4%]
I
2=33.9%
[3.4%–54.8%]
(n=42)
30.2%
[24.5%–36.3%]
I
2=81.8%
[75.9%–86.2%]
(n=40)
41.6%
[34.6%–48.7%]
I
2=75%
[64.2%–82.6%]
(n=29)
20.8%
[14.5%–27.8%]
I
2=85.4%
[80.7%–88.9%]
(n=36)
46.9%
[36.9%–57.1%]
I
2=93.7%
[92.2%–94.8%]
(n=41)
33.2%
[25.8%–41.1%]
I
2=92.5%
[91%–93.7%]
(n=57)
79.2%
[72.4%–85.2%]
I
2=70.2%
[59.7%–78%]
(n=45)
69.9%
[61.2%–77.9%]
I
2=79.9%
[73.3%–84.9%]
(n=41)
doi:10.1371/journal.pmed.1000267.t003
Table 4. Estimates of percentage of responses and resections in patients receiving mono chemotherapy versus combination
chemotherapy groups including the 95% confidence interval from the random effect model and number of assessable studies for
each group (n).
Group Mono Chemotherapy Combination Chemotherapy
Complete response
[95% CI]
(number of studies assessable)
2.2% [1.3%–3.3%]
I
2=20.8% [0%–49.7%]
(n=30)
5.3% [3.8%–7.0%]
I
2=48.3% [25.5%–64.1%]
(n=41)
Partial response
[95% CI]
(number of studies assessable)
25.8% [20.2%–31.8%]
I
2=78.8% [70.3%–84.9%]
(n=30)
34.7% [28.9%–40.9%]
I
2=79.5% [72.1%–85%]
(n=35)
Resection rate (group 1)
[95% CI]
(number of studies assessable)
80.8% [66.1%–92.1%]
I
2=93.9% [91.2%–95.7%]
(n=13)
66.2% [57.9%–74.0%]
I
2=77.1% [62.6%–86%]
(n=19)
Resection rate (group 2)
[95% CI]
(number of studies assessable)
27.3% [18.1%–37.5%]
I
2=87.7% [82.7%–91.3%]
(n=22)
33.0% [25.2%–41.3%]
I
2=87.3% [82.9%–90.6%]
(n=29)
doi:10.1371/journal.pmed.1000267.t004
Neoadjuvant Therapy in Pancreatic Cancer
PLoS Medicine | www.plosmedicine.org 8 April 2010 | Volume 7 | Issue 4 | e1000267importantly better patient selection. Thus, neoadjuvant treatment
and reassessment may identify those patients (both initially
resectable and non-resectable) presenting with rapid progressive
or disseminated disease at restaging who therefore have a very
poor prognosis and for whom surgery is unlikely to provide any
benefit. On the other hand, there is the potential risk for tumor
progression during neoadjuvant therapy, i.e. patients with initially
resectable tumors might present with local or distant tumor
progression at restaging, which might not have occurred in the
setting of an initial tumor resection. In addition, neoadjuvant
treatment protocols usually require histological confirmation
before initiation of therapy, resulting in additional invasive
diagnostic measures. Clearly, only randomized controlled trials
can clarify which of the hypothetical advantages/disadvantages
are real and which ones are not.
There is only one phase III randomized controlled trial being
carried out comparing neoadjuvant therapy and surgery with
surgery alone (NCT00335543) [38]. This multicenter trial has
been recruiting patients since June 2003 and has currently enrolled
less than a third of the originally planned 254 patients. Due to the
exceedingly slow recruitment, the study will be terminated before
reaching the target population.
In the future, phase III trials have to be carried out using
already established protocols comparing neoadjuvant therapy
followed by exploration and possibly resection, with immediate
exploration and resection if possible (and additional standard
palliative or adjuvant therapies in both arms). As our data point
out, this would be especially relevant in the group of borderline
resectable/unresectable tumors. As a prerequisite for such trials,
standard definitions of resectability and objective computed
tomography criteria should be applied.
The reasons why no other phase III randomized trials for
neoadjuvant therapy in pancreatic cancer have been carried out or
are currently recruiting patients is not known. It might be speculated
that patient recruitment is a problem. However, given the high rate of
‘‘neoadjuvant’’ treated patients with locally advanced/unresectable
tumors [6], this argument does not seem to be valid, at leastnot in this
group of patients. Another important problem might be the difficulty
to achieve a histological/cytological proof of the tumor; however, this
would also apply to palliative therapy in most cases. Obviously, there
is a plethora of different chemotherapeutic/radiotherapeutic regi-
mens being used in the neoadjuvant setting (Figure 2, Table S1), and
it might be difficult to agree on a specific protocol for a large multi-
institutional study. In addition, standardized and widely accepted
definitions of resectability criteria are lacking. And finally, it might
also be more tempting in terms of funding and publications to
perform small phase I–II trials with newer chemotherapeutic agents
and radiation protocols, instead of phase III trials with already
established protocols. In contrast to the lack of phase III randomized
controlled trials, we have identified 111 relevant studies, including 56
phase I–II trials of neoadjuvant therapy in pancreatic cancer.
Neoadjuvant Therapy for Resectable Pancreatic Cancer
In the group of patients deemed resectable before neoadjuvant
treatment, 88.1% of the patients were explored after restaging
Figure 5. Estimates of resection percentages in patients
following neoadjuvant therapy and re-staging including the
95% confidence interval from the random effect model and
number of patients for each study (n). Studies analyzing initially
resectable tumor patients are depicted in blue, initially non-resectable
tumor patients in green, and those including both (or not defined) in
black.
doi:10.1371/journal.pmed.1000267.g005
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who were judged resectable were resected after neoadjuvant
treatment. This rate is similar to published resection rates of
78%–96% in patients with resectable tumors that are explored
without neoadjuvant treatment [4,39]. Grade 3/4 toxicities
observed for neoadjuvant therapy (i.e. radiochemotherapy in
96.4%) were higher than the reported rates for adjuvant
chemotherapy but within the range of adjuvant radiochemother-
apy. An estimated median survival of 23.3 mo was observed for
the group of resectable tumor patients who were resected after
treatment. This is within the range of the median survival of
20.1–23.6 mo observed in patients who are resected followed by
adjuvant chemotherapy [20,21,40], and longer than the median
survival of 16.9–20.2 mo for patients who do not receive
adjuvant therapy (Figure 7) [20,21]. In conclusion, the available
evidence for resectable pancreatic cancer points to similar
resection rates with or without neoadjuvant therapy and similar
survival rates comparing neoadjuvant therapy followed by
resection versus resection followed by adjuvant therapy
(Figure 7).
Neoadjuvant Therapy for Non-resectable Pancreatic
Cancer
In our analysis 46.9% of the patients initially staged unresectable
underwent surgical exploration. Of them, 69.9% could be resected
successfully, leading to a resectability rate after neoadjuvant
treatment in this group of patients of a relevant 33.2% (with
comparable R0 resection rates as in the group of initially resectable
tumor patients). Morbidity and mortality rates following resection
were estimated higher in this group of patients as compared to
initially resectable tumor patients, most likely reflecting a more
extensive/aggressive surgical approach [41], rather than effects of
neoadjuvant therapy. For the group of patients who present with
locally advanced/unresectable disease, the median survival is 6–
11 mo[42,43]. Similarly, inouranalysis,patients initiallydiagnosed
as unresectable who were not resected had a median survival of
10.2 mo. In contrast, the 33.2% resected patients of the initially
non-resectable tumor patients had an estimated median survival of
20.5 mo, which is within the range of pancreatic cancer patients
with primary resection and adjuvant therapy. Patients who respond
to chemotherapy have a better prognosis than those who do not.
Therefore, one can only speculate about the survival time in
responding patients if they were not resected. However, the fact that
this subgroup of responding patients has the same median survival
as patients who underwent immediate resection suggests that the
increase in survival time for these patients can probably be
attributed to the better treatment (resection) and is not due to
patient selection. In conclusion, a relevant proportion, i.e.
approximately one third of patients initially staged as locally
advanced/unresectable, can be successfully resected following
neoadjuvant therapy with an estimated median survival within the
range of initially resectable tumor patients (Figure 7).
Response to Neoadjuvant Therapy
For the whole study cohort the number of patients with
complete response was 3.9% and partial response 29.1%. Thus,
approximately one third of the patients demonstrate radiographic
and/or histological response towards neoadjuvant therapy. These
response rates are relatively higher compared to data from
palliative chemotherapies (5.5%–14.5% response rate [3]), but
similar to published reports on combination chemotherapy (26.8%
response rate [44]). Stable disease was observed in 43.9% of the
patients, but progressive disease was detected in 20.8%. Interest-
ingly, the data did not differ much in the two groups of initially
resectable and non-resectable tumor patients, suggesting similar
tumor biology. Future trials will have to address response
prediction to identify the approximately one fifth of patients who
Figure 6. Funnel plots for the resection rate for studies analyzing initially resectable (A) and non-resectable (B) tumor patients.
Green line, average proportion; dashed blue line, upper and lower 3 SD limits; solid blue line, upper and lower 2 SD limits.
doi:10.1371/journal.pmed.1000267.g006
Table 5. Estimates of morbidity and mortality in patients
undergoing pancreatic resection following neoadjuvant
therapy including the 95% confidence interval from the
random effect model and number of assessable studies for
each group (n).
Group Morbidity Mortality
All patients 34.2%
[28.3%–40.4%]
I
2=75.8%
[68.2%–81.5%]
(n=50)
5.3%
[4.1%–6.8%]
I
2=29.2%
[7%–46.1%]
(n=85)
Tumor resectable before treatment (group 1) 26.7%
[20.7%–33.3%]
I
2=67.2%
[48.8%–79%]
(n=22)
3.9%
[2.2%–6.0%]
I
2=51.9%
[26.9%–68.3%]
(n=30)
Tumor non-resectable before
treatment (group 2)
39.1%
[29.5%–49.1%]
I
2=67.5%
[49.8%–78.9%]
(n=23)
7.1%
[5.1%–9.5%]
I
2=0%
[0%–23.4%]
(n=43)
doi:10.1371/journal.pmed.1000267.t005
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Interestingly, an analysis of trials with respect to monotherapy
versus combination chemotherapy revealed higher complete and
partial response rates in the combination therapy group. Higher
response rates, however, did not translate into higher resection
rates in the group of initially resectable tumor patients for mono-
versus combination therapy. In contrast, the combination therapy
resulted in an estimated 20% increase in the resection rate for
initially non-resectable tumor patients.
Inherently, a review based on retrospective and prospective
phase I–II trials, cohort studies, and case series has several
drawbacks:
Statistical considerations. Since no data from controlled
randomized trials were existent, comparison of subgroups could
solely be performed in a descriptive way. Although confidence
limits were reported for point estimates of primary interesting
proportions (frequency of exploration and/or resection), no
effect sizes allowing for direct group comparisons were
calculable. By estimating median survival times of study
populations, two critical assumptions had to be made: a
constant (time-independent) hazard rate and a similar
underlying mechanism of patient drop-out (censoring (rates)
due to lost follow-up or competing risks) within the trials.
Further, no limits of confidence could be provided for estimated
Table 6. Estimates of median survival times (mp) in months and survival probabilities.
Group Estimated Median Survival (mp) Estimated Survival Probability (Resected)
Resected (Range) Not Resected (Range) 1 Year (Range) 2 Year (Range)
All patients 22.4
(9–62)
(n=70)
9.5
(6–21)
(n=51)
78.9% (0%–100%)
I
2=48.1% [28.7%–62.3%]
(n=54)
49.2% (0%–82%)
I
2=85.2% [80.5%–88.7%]
(n=37)
Tumor resectable before treatment (group 1) 23.3
(12–54)
(n=27)
8.4
(6–14)
(n=19)
77.9% (48%–100%)
I
2=70.7% [52.6%–81.8%]
(n=18)
47.4% (25%–70%)
I
2=69.1% [42.2%–83.4%]
(n=11)
Tumor non-resectable before treatment (group 2) 20.5
(9–62)
(n=29)
10.2
(6–21)
(n=25)
79.8% (0%–100%)
I
2=92.1% [89.8%–93.9%]
(n=29)
50.1% (0%–82%)
I
2=88.6% [84%–91.9%]
(n=21)
n, number of assessable studies for each group.
doi:10.1371/journal.pmed.1000267.t006
Figure 7. Summary overview of survival and resection percentages of different groups of patients with pancreatic cancer. Note that
survival estimates derive from this systematic review and referenced studies.
doi:10.1371/journal.pmed.1000267.g007
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Potential Explanation
Factor Variable
Resection
Rate
Exploration
Rate CR PR SD PD Toxicity Morbidity Mortality
Institution 16.7% (17.4%) 13.3% (15.0%) 30.2% (31.9%) 20.9% (16.7%) 27.2% (10.7%) 12.8% (24.9%) 34.8% (35.2%) 20.8% (14.3%) 22.5% (19.6%)
Study design 1.2% (2.9%) 0.6% (1.6%) 3.1% (1.0%) 10.7% (4.0%) 4.1% (1.8%) 3.6% (6.9%) 3.8% (4.6%) 8.7% (2.0%) 2.3% (1.6%)
Chemotherapy 2.1% (3.1%) 0.8% (1.6%) 0.6% (8.1%) 6.0% (7.2%) 1.6% (0.8%) 0.2% (0.4%) 10.4% (2.4%) 0.1% (0.5%) 3.1% (6.8%)
Mean year of study
interval (decades)
2.0% (1.9%) 1.1% (0.2%) 0.2% (2.0%) 0.6% (6.7%) 2.3% (1.0%) 0.9% (7.0%) 2.2% (1.5%) 3.2% (2.0%) 10.4% (10.6%)
Mean patient age
(5-y intervals)
1.1% (1.1%) 1.2% (0.6%) 2.7% (1.1%) 3.4% (3.4%) 1.5% (1.8%) 1.4% (1.7%) 3.5% (2.6%) 9.9% (4.1%) 9.9% (4.6%)
Response evaluation
criteria
1.5% (3.4%) 2.7% (3.6%) 2.4% (0.1%) 2.6% (0.3%)
Resectability 14.0% (9.0%) 25.5% (10.5%) 1.0% (0.9%) 0.0% (2.6%) 4.1% (0.9%) 1.1% (8.1%) 0.3% (0.2%) 2.2% (4.9%) 0.6% (0.2%)
Resectability evaluation
criteria
0.1% (0.7%) 1.4% (0.7%)
The fraction of explained variance is given in %. Values in parentheses represent the fraction of explained variance in % from univariable analysis.
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
doi:10.1371/journal.pmed.1000267.t007
Table 8. Quality assessment.
Category Outcome
Resection
Rate
Exploration
Rate
Response
Evaluation Toxicity Morbidity Mortality Median Survival 1 y/2 y Survival
Number of
studies (range)
35–111 32–88 2–82 22–63 22–50 30–85 19–70 11–54
Study design Phase I–II trials Phase I–II trials Phase I–II trials Phase I–II trials Phase I–II trials Phase I–II trials Phase I–II trials Phase I–II trials
Cohort studies Cohort studies Cohort studies Cohort studies Cohort studies Cohort studies Cohort studies Cohort studies
Case series Case series Case series Case series Case series Case series Case series Case series
Limitations No serious
limitation
No serious
limitation
No serious
limitation
a
No serious
limitation
No serious
limitation
b
No serious
limitation
b
No serious limitation
c No serious limitation
d
Inconsistency Serious
inconsistency
e
Serious
inconsistency
e
Serious
inconsistency
e
No serious
inconsistency
f
No serious
inconsistency
g
No serious
inconsistency
h
Serious inconsistency
e Serious inconsistency
e
Indirectness
i
Imprecision
j No serious
imprecision
k
No serious
imprecision
k
No serious
imprecision
k
No serious
imprecision
l
Serious
imprecision
m
Serious
imprecision
n
Serious imprecision
o Serious imprecision
o
Other
considerations
Studies weighted by
number of initial patients
Studies weighted by
number of initial patients
Quality ++ ++ ++ +++ ++ ++ + +
Importance Critically
important
Important Important Important Important Critically
important
Critically important Critically important
The quality assessment for the indicated outcome parameters was carried out according to the grade profiler as described in the Methods section. +, very low; ++, low;
+++, moderate.
aSeparated evaluation of response categories, several evaluation criteria, proportions experiencing each type of response are not independent.
bBased only on resected patients.
cAssumption of uniform (exponential) distributed survival times.
dDifferent trials for estimating 1 y/2 y survival.
eHigh heterogeneity which could not be sufficiently explained by potential sources of variation within the meta-regression analysis.
fObvious heterogeneity partly explained by different chemotherapy treatment regimes within the trials.
gObvious heterogeneity partly explained by differences in mean patient age and study design between the trials.
hNo considerable heterogeneity obvious from the data.
iSince no direct comparison was feasible for any considered outcome measurement, indirectness has to be fixed as ‘‘very serious’’ for the entire topic of the
investigation.
jFor the same reason no particular measure of precision (e.g. confidence intervals) was available for any single trial considered; therefore, imprecision is rather crude
assessed in reference to the number of study participants within any meta-analysis.
kSubstantial sample sizes per study: median (IQR): 30 (18 to 47).
lSubstantial sample sizes per study: median (IQR): 29 (19 to 39).
mInsufficient sample sizes per study: median (IQR): 16 (7 to 25).
nInsufficient sample sizes per study: median (IQR): 13 (6 to 25).
oNo sufficient information about patients at risk.
doi:10.1371/journal.pmed.1000267.t008
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to be cautiously interpreted as crude estimates of central tendency.
Estimates of 1- and 2-y survival were provided as weighted averages. In
this term, the total number of study patients was used for weighting
because no sufficient information about patients at risk was available.
These estimates again assume similar censoring rates within the studies.
Further, because several studies had to be used for estimation of
survival probabilities, differences between these estimates do not
necessarily reflect the real change of survived individuals within one
and the same population about time. Frequencies of resection and
exploration showed a high heterogeneity (I
2 values.80%; see below)
between the trials. Consequently, although conservative random effect
models were used throughout for calculation, point estimates may not
reflect underlying latent varieties between the trials and may rather be
an artificial average and therefore confidence intervals have to be
particularly considered for interpretation.
Heterogeneity. Dealing with heterogeneity among study results
is one of the most important challenges in meta-analysis. This problem
c a nb ep a r t l yo v e r c o m eb yt h eu s eo fr a n d o me f f e c tm o d e l sw h i c h
consider within-study and between-study variability, as well as by
stratified analysis of homogeneous study subgroups. Further, meta-
regressionanalysescanbeusedforexplanationofheterogeneityinterms
of study-level covariates. In this analysis we have used random effect
models and carried out meta-regression analyses to assess sources of
heterogeneity. Institutions constituted an important source of
heterogeneity in our analysis, underscoring the role of individual
(center-specific) approaches/therapy algorithms even in high volume
centers of pancreatic surgery that are thought to have comparable
outcome parameters [4]. The age of the patients as well as the study
periodwereidentifiedasimportantvariablesforheterogeneityespecially
for perioperative morbidity and in-hospital mortality. Interestingly,
differences in the study design (e.g. phase I–II clinical trials, case series,
retrospective, prospective studies) had only minor impact on the
variability of resection/exploration rates but were an important source
of heterogeneity for response evaluation and morbidity.
Overlapping patient populations. There were 73 studies
from the 17 centers that published more than 1 report with probably
partially overlapping patient populations. Some patients might have
been included, e.g. in a prospective analysis, later in a comparative
analysis or in a retrospective study. Thus, there was the risk of
producing artificially precise estimates since the same data were
potentially tested multiple times (double counting). However, since the
overlapping studies often analyzed different outcome parameters (e.g.
toxicity evaluation, pathological response evaluation, etc.), we assumed
this risk minor and opted to include these partially overlapping studies.
Second, since a large number of outcomes were tested for the same
population (multiplicity), there was the risk of false estimates for some of
these outcomes. However, since only some studies overlapped, and
mostly only by a subset of their populations, we assumed the risk of
multiplicity moderate.
Definition of resectability. Resectability criteria and
especially definitions of borderline resectable/unresectable
tumors were variable. Thus, in more than 50% of the studies
resectability criteria were not or not clearly stated, thereby
constituting a potential source of bias. To minimize these effects
we grouped borderline resectable and unresectable tumors
together (termed non-resectable tumors), since the definition of
resectable tumors is more reliable than the differentiation of
borderline resectable and unresectable.
Conclusion
The present analysis provides the most comprehensive review
regarding neoadjuvant therapies in resectable and non-resect-
able pancreatic cancers to date—thus, the best actual available
evidence for response rates, treatment toxicities, resection rates,
morbidity and mortality, and survival estimates. The most
important findings are that in the group of resectable tumor
patients, resection and survival rates after neoadjuvant therapy
are similar to the ones observed in primarily resected tumor that
are treated by adjuvant therapy. Thus, in this group of patients,
the current data do not point to an obvious advantage of
neoadjuvant therapy. In contrast, in patients initially staged
locally advanced/unresectable, approximately one third of the
patients can be resected following neoadjuvant therapy with
comparable survival rates as patients who were staged as
resectable before treatment. Due to the heterogeneity of applied
protocols, data regarding the optimal chemotherapeutic and
radiotherapeutic regimen cannot be extrapolated; however, the
data suggest that combination chemotherapies result in higher
response rates, which is reflected by higher resection rates at
least in the group of initially non-resectable tumor patients.
Future trials have first to clearly establish the role of
neoadjuvant therapy specifically in locally advanced/unresect-
able tumors and subsequently to define optimal treatment
protocols. In addition, common definitions for resectability/
non-resectability as well as for response evaluation should be
applied. As of now, the available data strongly suggest that
patients with locally advanced/unresectable tumors should be
included in neoadjuvant protocols and subsequently be re-
evaluated for resection, which is possible in a relevant number
of patients.
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Background. Pancreatic cancer is the fourth leading cause
of cancer-related deaths worldwide. It begins when a cell in
the pancreas (an organ lying behind the stomach that
produces digestive enzymes and hormones such as insulin
that controls blood sugar levels) acquires genetic changes
that allow it to grow uncontrollably and, sometimes, to
spread around the body (metastasize). Because pancreatic
cancer rarely causes any symptoms early in its development,
it is locally advanced in more than a third of patients and has
already metastasized in another half of patients by the time
it is diagnosed. Consequently, on average, people die within
5–8 months of a diagnosis of pancreatic cancer. At present,
the only chance for cure is surgical removal (resection) of the
tumor, part of the pancreas, and other nearby digestive
organs. This procedure—the Whipple procedure—is only
possible in the fifth of patients whose tumor is found when it
is small enough to be resectable, and even in these patients,
the cure rate associated with surgery is less than 25%,
although radiotherapy or chemotherapy after surgery
(adjuvant therapy) can be beneficial.
Why Was This Study Done? For patients whose tumor
has metastasized, palliative chemotherapy to slow down
tumor growth and to minimize pain is the only treatment
option. But, for the many patients whose disease is locally
advanced and unresectable at diagnosis, experts think that
‘‘neoadjuvant’’ therapy might be helpful. Neoadjuvant
therapy—chemotherapy and/or radiotherapy given before
surgery—aims to convert unresectable tumors into
resectable tumors by shrinking the visible tumor and
removing cancer cells that cannot be seen with the naked
eye. Randomized phase III trials—studies in which groups of
patients are randomly assigned to different interventions
and specific outcomes measured—are the best way to
determine whether an intervention has any clinical benefits,
but no randomized phase III trials of neoadjuvant therapy for
unresectable pancreatic cancer have been undertaken.
Therefore, in this systematic review (a study that uses
predefined criteria to identify all the research on a given
topic) and meta-analysis (a statistical method for combining
the results of several studies), the researchers analyze data
from other types of studies to investigate whether
neoadjuvant therapy for pancreatic cancer provides any
clinical benefits.
What Did the Researchers Do and Find? In their
systematic review, the researchers identified 111 studies
involving 4,394 patients in which the effects of neoadjuvant
chemotherapy and/or radiotherapy on tumor response,
tumor resectability, and patient survival had been
investigated. They subdivided the studies into two groups:
group 1 studies included patients whose tumors were
considered resectable on preoperative examination, and
group 2 studies included patients whose tumors were
borderline resectable or unresectable. In their meta-
analysis, the researchers found that similar percentages of
the tumors in both groups responded to neoadjuvant
therapy by shrinking or regressing and that about a fifth of
the tumors in each group grew larger or metastasized during
neoadjuvant therapy. In the group 1 studies, three-quarters
of the tumors were resectable after neoadjuvant therapy (a
decrease in the proportion of tumors that could be treated
surgically) whereas in the group 2 studies, a third of the
tumors were resectable after neoadjuvant therapy (an
increase in the proportion of tumors that could be treated
surgically). After resection, the average survival time for
group 1 patients was 23.3 months, a similar survival time to
that seen in patients treated with surgery and adjuvant
therapy. The average survival time for group 2 patients after
resection was 20.5 months.
What Do These Findings Mean? The finding that the
average survival time after neoadjuvant therapy and surgery
in patients whose tumor was judged resectable before
neoadjuvant therapy was similar to that of patients treated
with chemotherapy and/or radiotherapy after surgery
suggests that for patients with resectable tumors,
neoadjuvant therapy will not provide any clinical benefit.
By contrast, the finding that a third of patients initially
judged unresectable were able to undergo resection after
neoadjuvant therapy and then had a similar survival rate to
patients judged resectable before neoadjuvant treatment
strongly suggests that patients presenting with locally
advanced/unresectable tumors should be offered
neoadjuvant therapy and then re-evaluated for resection.
Randomized trials are now needed to confirm this finding
and to determine the optimum neoadjuvant therapy for this
group of patients.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000267.
N The US National Cancer Institute provides information for
patients and health professionals about all aspects of
pancreatic cancer (in English and Spanish), including a
booklet for patients
N The American Cancer Society also provides detailed
information about pancreatic cancer
N The UK National Health Service and Cancer Research UK
include information for patients on pancreatic cancer on
their Web sites
N MedlinePlus provides links to further resources on
pancreatic cancer (in English and Spanish)
N Pancreatica.org, PancreaticDuct.org, and the Pancreatic
Cancer Action Network give more information to pancreatic
cancer patients, their families, and caregivers
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